<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">This is an open-labeled randomized superiority multicentric phase III studyin French academic hospital. Patients will randomized in a 1:1 ratio between (Fig.Â 
 <xref rid="Fig1" ref-type="fig">1</xref>): 
 <list list-type="bullet">
  <list-item>
   <p id="Par41">Arm A (experimental group): Standard care of treatment (systemic treatment suitable for primary cancer) and SBRT to the bone metastases.</p>
  </list-item>
  <list-item>
   <p id="Par42">Arm B (control group): Standard care of treatment (systemic treatment suitable for primary cancer) alone.</p>
  </list-item>
 </list>
</p>
